ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.13% | 12.44% | |||
| Depreciation & Amortization | -2.06% | 6.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.46% | 14.04% | |||
| Operating Income | 6.46% | -14.04% | |||
| Income Before Tax | -2.92% | 1.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.92% | 1.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.92% | 1.87% | |||
| EBIT | 6.46% | -14.04% | |||
| EBITDA | 6.63% | -14.18% | |||
| EPS Basic | -2.41% | 2.35% | |||
| Normalized Basic EPS | -1.92% | 1.89% | |||
| EPS Diluted | -2.41% | 2.35% | |||
| Normalized Diluted EPS | -1.92% | 1.89% | |||
| Average Basic Shares Outstanding | 0.62% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.62% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||